Euskadi strengthens its position as a European hub for biosanitary innovation, neuroscience, and health technologies after two major achievements
Bi topaketa hauek nabarmen indartzen dute sektore biosanitarioaren proiekzioa Euskadin
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities
Support the execution of a robust pipeline of customer projects for innovators developing groundbreaking in vivo and ex vivo cell and gene therapies.
‘Syngoi Technologies’: Columbus VP creates a new company in Bizkaia for synthetic DNA production
Columbus VP, a venture capital investment management company with a singular focus on business opportunities emerging in the biotechnology and life sciences sector.
The Basque Government participates in the Research and production project for the vaccine against COVID 19, together with Harvard and the company VIRALGEN
Tapia highlights that, once Harvard advances with the vaccine, the Basque Country is ready to take on this opportunity that represents a unique health, social and business advance
VIVEbiotech SL new member of the Board of Directors of the Spanish Bioindustry Association (AseBio)
AseBio brings together more than 730 companies that employ almost 100,000 people and invest more than € 400 million in R&D
VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan
in 2021 VIVEbiotech will be able to produce lentiviral vectors for advanced clinical trials
VIVEbiotech receives an issue notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office
LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the fact that it is not inserted into the genome of cells.
Columbus launches a €70 million fund for biomedicine
With the new investment fund, the managers plan to build two new plants in San Sebastian